×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
|
Dashboard
Analyses
Exchange
Gaps
←
Home
/
Wiki
/
Company: Astrocyte-Targeted Parkinson's Disease Therapies
company
943 words
KG: astrocyte
Contents
Astrocyte-Targeted Parkinson's Disease Therapies
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Related Hypotheses (30)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.38
Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro
Score: 0.61
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.92
CYP46A1 Overexpression Gene Therapy
Score: 0.92
SASP-Mediated Complement Cascade Amplification
Score: 0.91
Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.85
APOE-Dependent Autophagy Restoration
Score: 0.85
ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro
Score: 0.85
Circadian Glymphatic Entrainment via Targeted Orexin Recepto
Score: 0.84
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.82
AMPK hypersensitivity in astrocytes creates enhanced mitocho
Score: 0.81
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.79
Competitive APOE4 Domain Stabilization Peptides
Score: 0.78
SASP-Driven Aquaporin-4 Dysregulation
Score: 0.78
Selective HDAC3 Inhibition with Cognitive Enhancement
Score: 0.78
Prefrontal sensory gating circuit restoration via PV interne
Score: 0.78
Chromatin Accessibility Restoration via BRD4 Modulation
Score: 0.77
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.76
SASP-Mediated Cholinergic Synapse Disruption
Score: 0.76
Circadian Clock-Autophagy Synchronization
Score: 0.76
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.76
Multi-Modal Stress Response Harmonization
Score: 0.76
Senescence-Activated NAD+ Depletion Rescue
Score: 0.76
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.75
APOE Isoform Expression Across Glial Subtypes
Score: 0.74
Smartphone-Detected Motor Variability Correction
Score: 0.74
Senescent Cell Mitochondrial DNA Release
Score: 0.74
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.74
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.74
Show 25 more
Related Analyses (30)
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · completed
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Extracellular vesicle biomarkers for early AD detection
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Senescent cell clearance as neurodegeneration therapy
neurodegeneration · archived
Show 25 more
Related Experiments (30)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Show 25 more
See Also (6)
ABCA1 - ATP-Binding Cassette Transporter A1
gene · KG edge: expressed_in
ABCG1 Gene
gene · KG edge: expressed_in
ABCG4 Gene — ATP-Binding Cassette Subfamily G Member 4
gene · KG edge: expressed_in
ADAM10 — A Disintegrin And Metalloproteinase Domain 10
gene · KG edge: activates
ADNP Gene
gene · KG edge: expressed_in
ADORA1 Gene
gene · KG edge: activates
Show 1 more
Knowledge Graph (12 edges)
MAP1LC3B
expressed_in
astrocyte
CB2R
expressed_in
astrocyte
APOE
regulates
astrocyte
astrocyte
associated_with
Multiple sclerosis
NRF2
expressed_in
astrocyte
BMAL1
expressed_in
astrocyte
NOX4
expressed_in
astrocyte
STAT3
regulates
astrocyte
reactive_astrocyte
associated_with
astrocyte
C3
expressed_in
astrocyte
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)